Syntekabio-MDbiolab, Joint Drug Discovery Research Using AI 추진

[Asia Economy Reporter Lee Chun-hee] Syntekabio, an AI new drug development company based on genomic big data, announced on the 11th that it has signed a joint research agreement with MD BioLab, an innovative new drug development company.

This joint research will apply Syntekabio's compound-protein binding prediction AI platform, DeepMatcher technology, to study the biological mechanism of MD BioLab's small molecule drug candidate 'MD102'. The mechanism of action of MD102 will be clearly identified and followed by subsequent research such as indication expansion.

MD102 is a small molecule drug pipeline of MD BioLab that acts as a cancer-specific target transglutaminase 2 (TG2) inhibitor. Its anticancer efficacy has been confirmed in in vivo xenograft experiments, and it is currently being developed targeting kidney cancer. TG2 undergoes significant protein structural changes depending on the intracellular and extracellular environment, and its protein functions and related diseases also vary. Both companies expect that by utilizing DeepMatcher to predict the interaction mechanism between MD102 and TG2, they will be able to establish a foundation for future development strategies.

Jung Hyun-chul, head of research at MD BioLab, said, "Through this agreement, we expect to accelerate the innovative anticancer drug development project and expand indications, and we will continue to pursue an open collaboration strategy to strengthen future research and development (R&D) competitiveness.” Jung Jong-sun, CEO of Syntekabio, also said, "We are pleased to conduct research together with MD BioLab, which discovers new therapeutic target proteins and develops first-in-class drugs within its class,” adding, “We will do our best to ensure that our AI technology synergizes with traditional biological research and development capabilities to contribute to innovative drug development."

This content was produced with the assistance of AI translation services.